Vitality Launches Discounted Weight Loss Medications for UK Members
UK health insurer Vitality becomes the first in the country to offer discounted anti-obesity treatments to its members, addressing rising obesity rates and related health concerns.
Vitality, the third-largest health insurer in the UK, has announced that it will provide discounts on weight loss medications for its members, marking a significant move in the UK health insurance market.
With over 1.9 million clients, the company will offer up to 20% off popular anti-obesity drugs such as Wegovy and Mounjaro, contingent on members’ body mass index (BMI) and weight-related health conditions.
Members may apply for the new medication pathway by completing their health profile via the Vitality app.
Eligibility for the medications requires a BMI of 35 or higher, and successful applicants will receive coaching from a dietitian as well as discounted access to anti-obesity medications for a maximum of 12 months.
The initiative comes amidst the rising demand for anti-obesity drugs, which belong to a class known as GLP-1 receptor agonists.
These drugs work by mimicking the gut hormone that reduces appetite.
They are administered weekly through injections and have demonstrated efficacy in facilitating weight loss while also providing additional health benefits, including lowering the risk of heart attacks and kidney diseases.
The costs associated with these treatments are significant.
Wegovy, produced by Denmark’s Novo Nordisk, is priced in the UK at £139 for a one-month supply, with higher doses reaching up to £269.
The National Health Service (NHS) approved Wegovy for use in 2023, reporting an average weight reduction of approximately 15% within a year of treatment.
Mounjaro, developed by Eli Lilly, was approved as a second obesity treatment for the NHS in 2022. Its price also starts at £139 per month, with clinical trials indicating potential weight loss of about 20%.
The annual expense can reach approximately £1,435 at maximum dosage.
The introduction of discount medications is intended to complement Vitality’s existing weight loss initiatives, which utilize a reward-based approach to promote healthier lifestyles.
According to the company, nearly 48% of participants in these programs have achieved a 5% weight loss, which can lead to lower insurance premiums and various other incentives.
Obesity is a pressing issue in the UK, costing the NHS around £6.5 billion annually and contributing to serious health problems, including cardiovascular diseases, type 2 diabetes, and non-alcoholic fatty liver disease.
In the United States, the coverage of weight loss drugs in health insurance plans remains limited.
A survey published in the journal Health Affairs noted that less than 20% of large employers included such treatments in their offerings as of October 2023.
Dr. Katie Tryon, Chief Commercial Director at Vitality, stated that while some lifestyle-related risk factors, such as smoking and alcohol consumption, are declining, there is an increasing prevalence of obesity and associated challenges, which require urgent attention.
With over 1.9 million clients, the company will offer up to 20% off popular anti-obesity drugs such as Wegovy and Mounjaro, contingent on members’ body mass index (BMI) and weight-related health conditions.
Members may apply for the new medication pathway by completing their health profile via the Vitality app.
Eligibility for the medications requires a BMI of 35 or higher, and successful applicants will receive coaching from a dietitian as well as discounted access to anti-obesity medications for a maximum of 12 months.
The initiative comes amidst the rising demand for anti-obesity drugs, which belong to a class known as GLP-1 receptor agonists.
These drugs work by mimicking the gut hormone that reduces appetite.
They are administered weekly through injections and have demonstrated efficacy in facilitating weight loss while also providing additional health benefits, including lowering the risk of heart attacks and kidney diseases.
The costs associated with these treatments are significant.
Wegovy, produced by Denmark’s Novo Nordisk, is priced in the UK at £139 for a one-month supply, with higher doses reaching up to £269.
The National Health Service (NHS) approved Wegovy for use in 2023, reporting an average weight reduction of approximately 15% within a year of treatment.
Mounjaro, developed by Eli Lilly, was approved as a second obesity treatment for the NHS in 2022. Its price also starts at £139 per month, with clinical trials indicating potential weight loss of about 20%.
The annual expense can reach approximately £1,435 at maximum dosage.
The introduction of discount medications is intended to complement Vitality’s existing weight loss initiatives, which utilize a reward-based approach to promote healthier lifestyles.
According to the company, nearly 48% of participants in these programs have achieved a 5% weight loss, which can lead to lower insurance premiums and various other incentives.
Obesity is a pressing issue in the UK, costing the NHS around £6.5 billion annually and contributing to serious health problems, including cardiovascular diseases, type 2 diabetes, and non-alcoholic fatty liver disease.
In the United States, the coverage of weight loss drugs in health insurance plans remains limited.
A survey published in the journal Health Affairs noted that less than 20% of large employers included such treatments in their offerings as of October 2023.
Dr. Katie Tryon, Chief Commercial Director at Vitality, stated that while some lifestyle-related risk factors, such as smoking and alcohol consumption, are declining, there is an increasing prevalence of obesity and associated challenges, which require urgent attention.
